Last updated on June 2019

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)


Brief description of study

The primary purpose of this study is to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

Clinical Study Identifier: NCT03093480

Find a site near you

Start Over

University of Miami

Miami, FL United States
7.78miles
  Connect »